STUDresearch · Peptide

Pinealon

Also known as

EDR peptide · EDR · Glu-Asp-Arg · Glu Asp Arg · pineal bioregulator · Pinealon peptide · Khavinson EDR tripeptide · Cortexin-associated EDR (research context) · cytomed-class oral Pinealon (marketed bioregulator forms)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗

Peptide Some talk Systemic SubQ / Oral Longevity & bioregulators

Systemic — CNS/pineal-class bioregulator tripeptide discussed for brain, sleep, and gene-expression effects; not a local injury-site agent.

What people say Pinealon is a synthetic three-amino-acid peptide discussed for sleep, REM and brain fog—not a stimulant buzz.Reports are mixed, and Epitalon combinations make attribution difficult. Doses people talk about

Subcutaneous charts1–2 mg subcutaneously in total per day

One research-vial chart range; other charts disagree substantially. Not a validated safe range.

Older oral reports0.1–0.2 mg orally per administration, once or twice daily

Older adjunct-treatment accounts; not the research-vial context.

Oral capsule label confusionAbout 20 mg on some oral product labels

May refer to finished-product or excipient mass. This cannot be read as 20 mg of pure injectable Pinealon.

Different routes and products, not a low-to-high ladder. Capsule mass and injectable peptide amounts are not equivalent.

Half-life & effect duration

Half-life in the body: Community estimatesHours-scale; no agreed number
Felt duration people report: AccountsSame-day sensations, next-day changes or post-course carryover
Sleep reportsImproved sleep in some; disrupted sleep resolving after stopping in another

Timing context & sources

How it may feel People describe subtle sleep or clarity changes, while others notice little or nothing. Wearable changes are not the same as a proven brain effect.

Cycles people discuss Short injectable-course discussions often describe 10–20 days; older oral accounts describe 20–30 days. Repeated courses and breaks vary across communities. Timing Sleep-focused charts emphasize evening or pre-sleep use; some cognition logs describe morning or early-afternoon routines. There is no verified best hour across routes or products. Stacks Pineal pair (top stack): Pinealon + Epitalon (Epithalon) — community #1 for sleep/circadian/longevity dual coverage (neuronal/EDR vs telomerase/pineal AEDG narratives); no controlled combo RCT. Access talk How people talk about getting it: Gray-market lyophilized vials, oral bioregulator capsules, and occasional clinic charts. Watch for Injection site: Redness, sting, itch, swelling, or bruising with SubQ use—most common concrete community complaint.

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

A reliable human half-life was not established in the sources checked.

Hours-scale figures in community notes are estimates, not measured human clearance.

The accessible primary abstract describes cell experiments, not a human PK study. This bounded review does not prove that no study exists anywhere.

Khavinson et al.: Pinealon and cell viability (opens in a new tab)2011 paper, PubMed abstract; DOI 10.1089/rej.2011.1172Abstract reviewed, not the full paper. Cellular oxidative-stress/signaling work does not measure human elimination or validate a timing regimen.

Felt duration people report

Accounts describe same-day sensations, next-day changes and sometimes post-course carryover, without a consistent duration.

Sleep responses differ: one report describes improvement, while another describes disrupted sleep resolving after stopping.

Exercise, expectations, concurrent substances and unverified products confound these reports. Claims of nervous-tissue growth or lasting brain changes are not established by them.

Pinealon Timing — community account (opens in a new tab)Comment by No_Movie_3342, three timing experiments and intranasal-route statementUncontrolled individual report involving exercise and subjective sleep/cognition. Mechanistic and brain-growth claims are speculation and not adopted.
Pinealon experience — post-course follow-up (opens in a new tab)O_Cake_and_Quartz follow-up beginning with the reply to the description of a buzzy sensation; original post's Sleep sectionUncontrolled subjective follow-up with concurrent tirzepatide in the original report; persistent cognitive impressions are not objective measurement.

What people say 18

Brain fog (community): Less “heavy head,” easier to stay on a thought — second-loudest story after sleep. Some people notice nothing. forum
Memory & attention (community): Better working memory, focus, and “quiet fog” talk in aging or high-stress contexts—usually subtle, not stimulant-like. forum
Word-finding (quiet / minority): A few logs mention easier word memory or names on the tip of the tongue. Real talk, not a loud forum theme and not a fluency-drug claim. forum
Sleep & circadian (community): Deeper rest, easier nights, or more restorative sleep without hard sedation; some logs track higher REM share on wearables when stacked. forum
REM vs deep (community): Some n=1 / clip talk says REM share goes up while deep / slow-wave looks worse that night — a tradeoff argument, not a sleep-lab finding. anecdote
AM timing (minority): A few morning “for cognition” logs mention a wiped or groggy day. Not the main story — most sleep talk is night dosing. anecdote
REM / podcast halo: High-visibility n=1 claims (e.g., intermittent pre-sleep use ± glycine associated with much longer REM on personal trackers) drove search spikes—anecdote, not a controlled sleep trial. anecdote
Brain clarity logs: Quieter mental noise and steadier daytime focus over a short course rather than a same-day “nootropic buzz.” anecdote
Epitalon stack halo: Dual-pineal posts make single-agent credit unreliable when both run together. forum
TBI / cerebrasthenia adjunct narratives: Secondary writeups of small oral courses (~0.2 mg twice daily × ~20–30 days) cite improved memory, speech, headache burden, mood, and work capacity vs control arms in older Russian clinical reporting. trial
Older-age cerebral dysfunction: Khavinson-group reviews state oral Pinealon showed usefulness correcting cerebral dysfunction in older cohorts—still not a large Western Phase-3 package. trial
Neuroprotection (preclinical): Lower neuronal ROS, less necrosis under oxidative or excitotoxic stress, and better cell viability in cerebellar granule, neutrophil, and PC12 models. lab
ERK / cell-cycle nuance: Protective ROS drop saturates at lower concentrations while higher concentrations still shift cell-cycle/ERK timing—cited as genome-interaction evidence beyond simple antioxidant scavenging. lab
Dendritic spines (AD models): EDR preserved mushroom-type spines in Alzheimer-model cultures—mechanistic interest, not proven dementia therapy. lab
Prenatal hyperhomocysteinemia (rats): Maternal Pinealon improved offspring spatial learning/Morris maze performance and reduced cerebellar ROS/necrosis after methionine load. animal
Diabetes / learning retention (rats): Maintained learning retention in experimentally induced diabetes models in the Russian literature. animal
Serotonin / cortical gene talk: Originator-line work discusses serotonin-related expression and neuroplasticity markers in cortex models—mechanistic narrative more than clinic endpoint. lab
What it is not proven for: No high-quality Western evidence it treats Alzheimer’s, prevents dementia, cures TBI, or extends human lifespan. trial

Doses people talk about 19

Podcast / oral settlement range: Discussed oral self-experiment bands roughly ~0.5–3 mg/day in Western commentary, while older Russian capsule strengths near ~200 mcg are also named—shows how oral talk spans micro to low-mg. forum
Injectable micro (Eastern-European clinical-pattern writeups): ~100–300 mcg (0.1–0.3 mg) subcutaneous once daily for ~5–20 days. forum
Injectable mid (common research-chem charts): ~1–2 mg subcutaneous once daily for ~10–20 consecutive days from 10–20 mg lyophilized vials. forum
Injectable high community convention: ~5–10 mg subcutaneous once daily × ~10–20 days — frequently tied to 10 mg vial packaging math (one half-to-full vial/day), not a published human dose-finding study. forum
Long micro titration minority: Occasional 12-week educational ramps (~200 → 500 mcg/day) appear online; far less common than short Khavinson-style blocks. forum
Timing — cognition narrative: Morning or early afternoon preferred when the goal is daytime clarity. forum
Timing — sleep/REM narrative: Evening or pre-sleep (sometimes intermittent, not every night) when REM/circadian stories dominate; late dosing can conflict with morning-clarity goals. forum
Split vs once-daily: High charts sometimes split AM/PM; most SubQ writeups are once daily. forum
Unit math traps: Confusing mcg clinical microdoses with multi-mg research charts is the #1 error; also confusing oral finished-product mg with pure peptide mg. forum
Why high charts persist: 10 mg vials make 5–10 mg/day a tidy whole-vial habit even when published human oral work used sub-milligram totals. forum
Uncertainty: Gray-market purity, sequence confirmation, and oral vs injectable product identity may not match label claims. forum
Nasal minority (2026): Some vendor/forum charts discuss low-mg nasal for CNS. That is not equivalent to 5–10 mg SubQ vial math and not the oral ~0.2 mg BID clinical micro band. forum
Russian marketed oral bioregulator capsules: Some protocol pages cite ~20 mg oral once daily × ~10–20 days for Cytomed-style capsule products — may reflect finished-product mass/excipient labeling rather than pure free-peptide milligrams equivalent to research vials; do not assume 20 mg capsule = 20 mg injectable EDR. forum
Injectable mid titration examples: Educational charts step ~1.0 mg early course → ~1.5–2.0 mg later days within a 10–20 day block (vendor-style, not trial-derived). forum
Clinic marketing templates: Some Western peptide-clinic pages list ~5 mg/day entry and up to ~10 mg/day “intensive,” or ~1 mg five days/week morning dosing — still off-label / non-FDA. forum
Oral clinical micro band (most-cited human narrative): ~0.1–0.2 mg once or twice daily orally for ~20–30 days (often written ~0.2 mg BID) in post-traumatic cerebrasthenia / cognitive-adjunct writeups. trial
Animal scale (not human conversion recipes): Rodent work spans ~50–200 ng/kg and ~10 µg/kg IP daily for multi-day windows (e.g., prenatal hyperhomocysteinemia protection) — cannot be linearly scaled to multi-mg human SubQ charts. animal
In-vitro concentrations: Micromolar dish exposures for ROS/viability endpoints — not injectable milligram guidance. lab
Framing: Community, clinic-marketing, and literature discussion ranges only — not advice, not prescriptions, not FDA-labeled dosing. Ranges disagree by orders of magnitude; treat that disagreement as a core fact. forum

How it may feel 9

Days 1–3: Little acute change for many; sleep-goal users sometimes claim slightly easier onset or first richer-dream nights if dosed evening. forum
Days 4–10: Common window for mild sleep-quality, REM-share, or mental-clarity notes—still not stimulant-like. forum
End of 10–20 day injectable course: Calmer cognition/sleep “settle” for responders, or “too subtle / nothing” for a large minority. forum
Days–weeks post-course: Residual sleep or clarity framed as lasting after blood presence ends—classic bioregulator “after the course” lore. anecdote
Wearable n=1 stacks: Some dual Epitalon+Pinealon logs report sleep-score, RHR, and HRV shifts within ~2 weeks—confounded, uncontrolled. anecdote
Months 3–6: Re-run talk on a ~2–4×/year calendar rather than daily forever. forum
Intermittent sleep experimenters: Podcast-style “infrequent tiny pre-sleep dose” users claim multi-night REM carryover; others report zero change—expectation and tracker noise are huge. anecdote
Hit-or-miss (still the 2025–2026 split): Wearable REM/sleep-score jumps vs “felt nothing” remain the two loud camps. forum
End of 20–30 day oral micro course: Historical clinical narratives emphasize functional cognitive/headache gains more than an on-drug rush. trial

Around the dose 7

Clock: Evening / pre-sleep in most nootropic-peptide charts. forum
Sleep: The pairing. Pinealon as a daytime stimulant is not the culture. forum
Learning: Some cognitive logs still add a quiet learning block; most treat it as a night peptide. forum
First-night stack caution: Community notes warn about combining several nighttime CNS peptides on night one; sleep, clarity and adverse effects then become difficult to attribute to Pinealon. forum
Split stack clock: 2026 X/forum logs sometimes run Pinealon AM (clarity) and Epitalon PM (sleep/circadian) — discussion pattern, not a trial protocol. forum
Not a DSIP pin: DSIP/Emideltide is a different night peptide. Stacking both as “sleep peptides” confounds credit. forum
Wearable habit: People who chase REM often dose evening and check the tracker the next morning — expectation noise is huge. forum

Cycles people discuss 9

Short injectable blocks: 10–20 consecutive days is the dominant gray-market / bioregulator-style pattern. forum
Shorter pulses: Some Eastern-European clinical-pattern summaries use ~5–10 day microdose pulses. forum
Off periods: Courses every ~3–6 months (~2–4× yearly) is the common calendar; some say 1–3 courses/year. forum
Continuous daily: Less common and framed non-standard vs classic short bioregulator calendars. forum
5 days on / weekend off: Minority clinic-style templates (~1 mg five days/week) appear in marketing copy. forum
Intermittent sleep experiments: Infrequent pre-sleep micro use rather than a full 20-day course—podcast-driven, not literature-standard. anecdote
Re-runs: Seasonal, after poor sleep/cognitive load, or stacked with yearly Epitalon courses; multi-year controlled safety data thin. forum
Course totals (illustrative community math only): Micro courses may total only a few milligrams over a month; 5 mg × 20 days implies ~100 mg total—orders-of-magnitude spread underscores protocol chaos. forum
Extended oral micro: ~20–30 day blocks in older adjunct clinical writeups. trial

Timing 8

Forum half-life lore: Community notes describe an hours-scale peptide and daily rather than weekly use during a course. The hours-scale estimate is not measured human clearance and does not establish a dosing interval. forum
Why short courses: Bioregulator practice + gene-expression / chromatin stories, not long plasma half-life “coverage.” forum
After course: Claimed sleep/cognitive steadiness days–weeks past presumed blood presence—“carryover” is anecdote. anecdote
REM multi-night claims: Some intermittent dosers claim elevated REM on subsequent nights without redosing—tracker n=1 only. anecdote
Route timing: Oral often AM/PM split in clinical micro narratives; injectors usually once daily SC; no head-to-head human PK. forum
BBB talk: Short tripeptide size is used to argue blood–brain access; quantitative human CNS PK not established. forum
Oral bioavailability debate: One camp cites historical oral clinical use as proof short EDR can work orally; another says typical peptides die in the gut and only SC research vials count—community remains split. forum
PK honesty: Formal human half-life, bioavailability, and brain-exposure packages for gray-market Pinealon are sparse to absent. trial

Stacks 9

Pineal pair (top stack): Pinealon + Epitalon (Epithalon) — community #1 for sleep/circadian/longevity dual coverage (neuronal/EDR vs telomerase/pineal AEDG narratives); no controlled combo RCT. forum
Example dual log: Public biohacker logs sometimes run ~0.5 mg Epitalon + ~1 mg Pinealon daily for multi-week sleep-metric experiments—illustrative only. anecdote
Glycine adjacency: Pinealon ± oral glycine for REM/sleep quality appears in podcast-adjacent discussion; confounded and not a trial protocol. forum
Khavinson multi-organ kits: With Cortagen (brain), Vesugen (vascular), Thymalin (immune), and other cytomed-class bioregulators on rotating calendars. forum
Sleep adjacency: DSIP, melatonin hygiene, magnesium/glycine, or GH-axis sleep peptides—credit is heavily confounded. forum
Cognition adjacency: Semax or Selank co-mention for focus/anxiety layers; no controlled Pinealon combo data. forum
Vs Epitalon alone: Users who want telomere/longevity emphasis pick Epitalon; those chasing REM/clarity or TBI-adjacent cognition talk add or prefer Pinealon—marketing overlap is high. forum
Lifestyle stack: Fixed sleep schedule, morning light, training load, and alcohol reduction often share credit with any peptide course. forum
2026 “sleep stack” revival: Pinealon + Epitalon nightly courses circulated as a REM/circadian pair — still no combo RCT; credit messy. forum

Access talk 3

How people talk about getting it: Gray-market lyophilized vials, oral bioregulator capsules, and occasional clinic charts. forum
Identity risk: Sequence/COA talk matters because “pineal” branding also gets used for Epitalon and crude epithalamin. forum
Not on the July 2026 PCAC seven. Emideltide (DSIP) was; the committee did not recommend it. Pinealon is a different molecule (Glu-Asp-Arg). trial

Storage notes 2

No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Related 8

Watch for 15

Injection site: Redness, sting, itch, swelling, or bruising with SubQ use—most common concrete community complaint. forum
Nonspecific systemic: Headache, mild fatigue, lightheadedness, nausea, or GI discomfort reported in a minority. forum
Sleep architecture shifts: Vivid dreams, temporarily altered sleep timing, or paradoxically lighter sleep if timing fights the goal. anecdote
Daytime vs night conflict: Evening dosing for REM can leave some users groggy or “off schedule”; morning dosing can miss sleep aims. forum
High-chart fatigue: Occasional mental exhaustion or overstimulation talk on multi-mg daily charts. anecdote
Source quality: Gray-market contamination, underdosed vials, wrong sequence, residual solvents, or mislabeled “Pinealon” products. forum
Dose-identity chaos as a safety issue: Running 5–10 mg/day because a vial is 10 mg when historical oral human narratives used ~0.2 mg BID is an unvalidated leap—risk of needless exposure. forum
CNS caution talk: General caution appears in clinic writeups for seizure-history populations with any CNS-active peptide—hard outcome data specific to Pinealon is thin. forum
Research-only / legal status: Jurisdiction varies; often sold “not for human consumption” while used contrary to labels; not an FDA-approved drug. forum
Not a dementia or TBI drug: Quiet side-effect threads ≠ long-term safety proof; preclinical AD/TBI interest ≠ approved indication. forum
No 503A pathway in 2026 trackers: Access talk is research-chem vials, oral cytomed-class capsules, and clinic-style charts — not a bulks-list listing. forum
Limited human safety package: Few English dedicated modern RCTs; “well tolerated” is often extrapolated from small cohorts, animal work, or marketing—not a full Phase-1–3 safety database. trial
Single-program evidence risk: Much of the published preclinical and clinical narrative originates from one research lineage—independent replication remains limited. trial
Pregnancy / lactation: Safety not established; animal prenatal-protection studies are not human clearance to use. trial
Do not confuse with Emideltide: Emideltide = DSIP. It was the one July 2026 PCAC peptide voted down. Pinealon had no vote that week. Mixing the names is a 2026 compounding-headline error. trial

Updated: 2026-09-01

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.

↑ Back to top

Half-life & effect duration

Timing context & sources⌄

Half-life in the body

Felt duration people report

What people say 18

Doses people talk about 19

How it may feel 9

Around the dose 7

Cycles people discuss 9

Timing 8

More on what it is 8

Stacks 9

Access talk 3

Storage notes 2

Related 8

Watch for 15

Timing context & sources